PDCD1 and non-small cell lung carcinoma: In conclusion, these data demonstrate that budigalimab has a manageable safety profile with evidence of biologic and clinical activity in patients with previously treated HNSCC and NSCLC that seems to be similar to approved PD-1 inhibitors.